programmed death receptor ligand-1 (PD-L1)
<p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer</p>
... of programmed death receptor-1/programmed death ligand 1 (PD-1/PD-L1) can stimulate surrounding T cells and thus have antitumor effects in the ...PD- ...
17
Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients
... Results: A total of 65 patients of lung adenocarcinoma were enrolled. They underwent complete resection and had recurrence after adjuvant treatment. PD-L1 expression was identified in 43.1% (28/65) of resection samples ...
5
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
... The interaction between PD-L1 and the PD-1 receptor on T cells leads to an inhibitory signal that constrains the function of activated lymphocytes [33]. Thus, PD-L1 overexpression is postulated to be a ...
12
The effect of chemotherapy on programmed cell death 1/ programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response
... (Table 1). PD-1 and PD-L1 antibodies have shown considerable clinical efficacy and durability across a range of malignancy subtypes, including melanoma and lung cancer [9, 58] and most recently in ...
10
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
... anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibody has a good effect in the treatment of non-small cell lung cancer (NSCLC), but ...
6
Wnt/beta-catenin pathway: modulating anticancer immune response
... Anti- programmed death-1; anti-PD-L1: Anti-programmed death ligand-1; APC: Adenomatous polyposis coli; CBP: cAMP response element-binding (CREB)-binding protein; COX-2: ...
12
A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction
... Accumulating evidence has demon- strated that the PD-1/PD-L1 pathway plays an important role in regulating the immune-inflammatory response during sepsis, as sepsis can upregulate PD-L1 expression on a variety of ...
11
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma
... Programmed death 1 (PD-1) receptor is an inhibi- tory T cell receptor expressed by activated T-cells and engaged by ligands PD-L1 and PD-L2 of the B7-ligand superfamily ...
5
Upregulation of programmed death 1 on T cells and programmed death ligand 1 on monocytes in septic shock patients
... the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway by anti-PD-L1 antibody decreased apoptosis of human peripheral T cells from septic patients ...
9
CXCR2–CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma
... CXC receptor 2; CXCL1: CXC ligand 1; RFS: Recurrence-free survival; OS: Overall survival; PD-L1: Programmed cell death 1 ligand 1; Treg: Regulatory T; MMP9: Matrix ...
10
Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives
... PD‑1: programmed cell death 1; PD‑L1: programmed cell death 1 ligand 1; CTLA4: cytotoxic T‑lymphocyte‑associated antigen‑4; DC: dendritic cell; TME: tumor ...
11
Original Article PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes
... and programmed death ligand 1 (PD-L1) were expressed on T-cell, B-cell, DC and ...one receptor of co-inhibitor, programmed death 1 (PD-1) was mainly ...
10
CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment
... PD-1: Programmed cell death receptor-1; PD-L1: Programmed cell death ligand-1; NSCLC: Non- small-cell lung cancer; ADC: Adenocarcinoma; SCC: Squamous cell ...
15
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
... factor receptor (EGFR), vascular endo- thelial growth factor (VEGF), mammalian target of rapa- mycin (mTOR), insulin-like growth factor 1 receptor (IGF-1R), or fibroblast growth factor ...
8
Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
... The relationship between PD-L1 expression and patients’ response rate to anti-PD-1/PD-L1 immuno- therapy was also not clear [27]. In the phase 1b KEY- NOTE-012 study of 39 patients, pembrolizumab showed promising ...
14
Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
... factor receptor mutation and rearranged anaplastic lymphoma kinase genes were not ...anti-acetylcholine receptor antibody, antinuclear antibody and anti-glutamic acid decarboxylase antibody did not show ...
5
Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma
... of agreement on PD-L1 among different methods. The extent of concordance among three validated, commercially available PD-L1 IHC assays (Dako 22C3, Ventana SP263, and Dako 28-8) was compared in 493 non-small-cell lung ...
5
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
... The most important finding of this study is in unambiguous definition of the druggable “hot spots” [30-32] at the surface of PD-L1 suitable for targeting with low-molecular weight inhibitors. Even though the atomic ...
13
Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
... In this study, we investigated a study cohort of 383 gastric cancer patients in the TCGA database and 300 patients in the GEO cohort, and generated stromal scores using the ESTIMATE algorithm. Our results showed that the ...
13
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
... file 1: Table S1Tables S4 and S5) were synthe- sized (Sigma-Aldrich) and used to stimulate T-cells in vitro for 10 days as previously described ...criteria: 1) significant expansion (Fisher’s exact test ...
8